Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Scott H. Kaufmann, M.D., Ph.D., is an oncologist at Mayo Clinic who also conducts research to study what happens when cancer cells are treated with targeted anti-cancer agents. Research in Dr. Kaufmann's Anticancer Drug Action Laboratory focuses on two major questions: 1) What is the biochemical basis for cell killing when it occurs, and 2) What can happen to cancer cells to make them resistant to these treatments. Within the context of these broad questions, Dr. Kaufmann's lab applies a wide range of biochemistry, cell biology and molecular biology approaches to a series of projects.
Collectively, studies in Dr. Kaufmann's lab are designed to improve the therapy of cancer. These studies simultaneously provide new insight into the action of targeted anti-cancer agents and identify biochemical features that contribute to treatment sensitivity or resistance. Dr. Kaufmann works with the Mayo Clinic Comprehensive Cancer Center's Early Cancer Therapeutics Group to translate these findings in the context of phase 1 and phase 2 clinical trials for ovarian cancer, other solid tumors and acute leukemias.
Learn about clinical trials that address specific scientific questions about human health and disease.
See my studies.
Explore all research studies at Mayo Clinic.
See the peer-reviewed findings I have published as a result of my research.
Review my research fingerprint, network, grants, projects, publications, Scopus profile, and Altmetrics scores and badges.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.